Dr. Martin Pfister

OMEICOS Therapeutics is a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company's novel therapeutic strategy is based upon the discovery of natural CYP-P450 generated metabolites of omega-3 fatty acids, so called epoxyeicosanoids. This new class of bioactive lipid mediators activates type specific cellular endogenous pathways that can be therapeutically deployed in inflammatory, cardiovascular, and other diseases. OMEICOS has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids. These small molecules are orally available and show significantly improved biological activity and pharmacokinetic properties compared to their natural counterparts. The first development project makes use of the strong anti-arrhythmic effect of the compounds for the development of an oral therapy for atrial fibrillation. In contrast to all other anti-arrhythmic drugs that act almost exclusively via direct inhibition of ion channels, OMEICOS'​ substances activate an endogenous cardio-protective signalling pathway that not only stabilizes the heart rhythm, but also provides curative effects to the diseased organ by preventing its electrical and structural remodelling. OMEICOS was founded as a spin-off from the Max-Delbrück-Center in Berlin. Its technology is based on ground breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders Drs. Wolf-Hagen Schunck, John. R. Falck, Dominik Müller and Robert Fischer.

HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed approx. 800 start-ups and successfully sold shares in 200 companies. HTGF has over 2 billion euros of fund volume. Fund investors in the public-private partnership include the German Federal Ministry of Economics and Energy, KfW Capital and 45 companies.

OMEICOS Therapeutics is a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company's novel therapeutic strategy is based upon the discovery of natural CYP-P450 generated metabolites of omega-3 fatty acids, so called epoxyeicosanoids. This new class of bioactive lipid mediators activates type specific cellular endogenous pathways that can be therapeutically deployed in inflammatory, cardiovascular, and other diseases. OMEICOS has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids. These small molecules are orally available and show significantly improved biological activity and pharmacokinetic properties compared to their natural counterparts. The first development project makes use of the strong anti-arrhythmic effect of the compounds for the development of an oral therapy for atrial fibrillation. In contrast to all other anti-arrhythmic drugs that act almost exclusively via direct inhibition of ion channels, OMEICOS'​ substances activate an endogenous cardio-protective signalling pathway that not only stabilizes the heart rhythm, but also provides curative effects to the diseased organ by preventing its electrical and structural remodelling. OMEICOS was founded as a spin-off from the Max-Delbrück-Center in Berlin. Its technology is based on ground breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders Drs. Wolf-Hagen Schunck, John. R. Falck, Dominik Müller and Robert Fischer.

HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed approx. 800 start-ups and successfully sold shares in 200 companies. HTGF has over 2 billion euros of fund volume. Fund investors in the public-private partnership include the German Federal Ministry of Economics and Energy, KfW Capital and 45 companies.

biosaxony is the association of the biotechnology/medical technology sector in the region of Saxony. Its members represent the various companies, research institutes and lobbyists working in biotechnology and medtech and the related areas of engineering and material sciences in Saxony. It pulls the different strands of biotech and medtech together, gauges its members’ needs, and represents their interests. biosaxony’s responsibilities include initiating projects between industry and research, pinpointing services and know-how, harnessing synergies, and highlighting regional expertise in order to support the value-added development of these cross-cutting technologies. Other elements of its cluster work include developing new ideas and strategies as well promoting sustainable technology transfer, such as at its partnering conference bionection. Local work is strengthened by biosaxony’s two offices in Leipzig and Dresden. In 2016, biosaxony set up the Section Medical Technology. Combining biotechnology with medical technology is intended to enable new areas of innovation to be identified, network actors from different fields, and hence lastingly strengthen the regional economic structure of both sectors. Imprint: https://www.biosaxony.com/en/imprint Privacy Policy: https://www.biosaxony.com/privacy-policy-linkedin-en

data information intelligence (dii), an Economist Intelligence Unit, is a full service marketing consulting company specializing in healthcare markets, with a particular focus on diagnostics and medical devices. We compile healthcare market data using a variety of sources, transform data into market information and convert it through different tools in business intelligence to assist with strategic decisions. We can build credible market models, determine user requirements, evaluate penetration rates, identify high value markets and determine the viability and value of new products. This has enabled our clients to minimize risks and turn business opportunities into commercial successes, whether launching first-to-market products, entering new markets or growing existing ones. We conduct customized market research, either tailored to the needs of one company with proprietary output, or so called multi client studies, which are developed in co-operation with interested companies to share costs and results. Please visit us at https://www.dii-healthcare.com